Health Care
Bio Ventures For Global Health
SEATTLE, WA
Total revenue
$505K
Total expenses
$2.6M
Net assets
$5.1M
Grants received
$88K
3 grants
EIN
300213137
Tax year
2024
Mission
BVGH builds partnerships to expand access to healthcare in LMICs, by strengthening health systems, coordinating national planning, building capacity, and managing procurement. Its work aligns and informs government and industry strategies and policies.
Programs
2 programs
BVGH Other Programs: BVGH develops and manages programs that advance LMIC government objectives as they relate to: public-private partnership development; strategic and implementation planning development; program implementation and management; and international partner program management (across research, health systems strengthening, workforce development, and climate and agriculture as they intersect with health). BVGH develops market assessment and entry reports for the private sector to inform short and long-term investments and decision making. Market reports include: economic and country stability and risk assessment; country SWOT analysis; market and growth potential; regulatory and payor systems analysis; innovative financing opportunities; stakeholder mapping; and more. Other programs include: laboratory and medtech systems placement, delivery, and training.
BVGH Infectious Disease Programs (Global Innovation Alliance (GIA) and Global Innovation Alliance Network of Trial Sites (GIANTS)): BVGH catalyzes and manages global cross-organization, cross-sector collaborations to advance research and development (R&D) targeting infectious diseases with high burdens in LMICs. Through the Global Innovation Alliance (GIA), BVGH: 1.) builds and manages R&D collaborations between LMIC scientists and global partners; 2.) assesses, promotes, and fosters clinical trial capacity and inclusion in LMICs; 3.) elevates scientific expertise in LMICs through tailored capacity building programs; and 4.) evaluates and communicates program outcomes and impacts to broad and targeted global audiences. The programs strengthen laboratory capacity, support technology transfer, and advance co-developed R&D initiatives for vaccines, therapeutics, and diagnostics. By integrating country-level health system knowledge with real-world implementation data, BVGH helps partners accelerate innovation and prepare for feasible adoption pathways. This work contributes to more resilient infectious disease response systems and informed policy decision-making.
Financials
FY 2024
Revenue
Expenses
People
11 listed
Jennifer Dent
President & CEO
$434K
40 hrs/wk
Jim Geraghty
Chair
—
2 hrs/wk
Rachel King
Director
—
1 hrs/wk
Ruth Atherton
Director
—
1 hrs/wk
Belinda Termeer
Director
—
1 hrs/wk
Dr Julie Gralow
Director
—
1 hrs/wk
Seringe Magueye Gueye
Director
—
1 hrs/wk
J Leighton Read MD
Director
—
1 hrs/wk
John Nevergole
Director
—
2 hrs/wk
Katy Graef
Vice President Programs
$190K
40 hrs/wk
Cathyryne Manner
Vice President
$170K
40 hrs/wk
Grants received
Showing 3 of 3
Funded by
$88K from 3 funders · 3 grants · 2021–2024
$50K · 1 grant · 2023
$25K · 1 grant · 2021
$13K · 1 grant · 2024